<code id='705B8A7B8E'></code><style id='705B8A7B8E'></style>
    • <acronym id='705B8A7B8E'></acronym>
      <center id='705B8A7B8E'><center id='705B8A7B8E'><tfoot id='705B8A7B8E'></tfoot></center><abbr id='705B8A7B8E'><dir id='705B8A7B8E'><tfoot id='705B8A7B8E'></tfoot><noframes id='705B8A7B8E'>

    • <optgroup id='705B8A7B8E'><strike id='705B8A7B8E'><sup id='705B8A7B8E'></sup></strike><code id='705B8A7B8E'></code></optgroup>
        1. <b id='705B8A7B8E'><label id='705B8A7B8E'><select id='705B8A7B8E'><dt id='705B8A7B8E'><span id='705B8A7B8E'></span></dt></select></label></b><u id='705B8A7B8E'></u>
          <i id='705B8A7B8E'><strike id='705B8A7B8E'><tt id='705B8A7B8E'><pre id='705B8A7B8E'></pre></tt></strike></i>

          leisure time

          leisure time

          author:knowledge    Page View:419
          Stock illustration of computer and medication
          Adobe

          Half a year after selling its assets at bankruptcy auction, Pear Therapeutics’ most significant digital treatments will find a new life as part of PursueCare, which provides online addiction care and mental health counseling.

          PursueCare today announced it had raised a $20 million Series B round and that it had acquired Pear’s portfolio of apps that treat people with addiction problems. PursueCare’s CEO Nick Mercadante told STAT the company hopes to develop the market for the treatments where Pear could not, by taking advantage of its access to patients and insurers.

          advertisement

          “My view of digital therapeutics is that those point solutions really need a horse to draw the carriage,” he said. “You need a willing and capable service provider that says we’re going to make this a big part of real world care and… then show the health plans how it can save them money in the real world without extra thinking.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          Ethical issues complicate the benefits of medical crowdfunding
          Ethical issues complicate the benefits of medical crowdfunding

          APStockMedicalcrowdfunding—usingsocialnetworksandmediatoraisefundsformedicaltreatment—isgrowinginpop

          read more
          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more

          Weighted lottery helped low

          AmedicalassistantataUniversityofWashingtonMedicineclinicpreparesatwo-shotdoseofEvusheldinJanuary2022